Uveitis
Not recruitingStudy of Baricitinib and Adalimumab for Children Aged 2 to 17 with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
Study of Baricitinib and Adalimumab for Children Aged 2 to 17 with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
- Disease:Uveitis
- Substances:AdalimumabBaricitinib
Germany- Participants:0–17 years
- Substances:Adalimumab
- Sponsor:Eli Lilly & Co.














